No Data
Revenues Not Telling The Story For Shanghai Fudan Forward S&T Co., Ltd (SHSE:600624) After Shares Rise 26%
Shanghai Fudan Forward S&T (600624.SH): The holding subsidiary's Pharmaceutical has passed the consistency evaluation for generic drugs.
On February 5th, GELON Group announced that its subsidiary Shanghai Fudan Forward S&T Pharmaceutical Co., Ltd. (referred to as "the Pharmaceutical Company") received the approval notice from the National Medical Products Administration regarding the supplementary application for Tamoxifen Citrate Tablets (referred to as "the Pharmaceutical"). This Pharmaceutical has passed the consistency evaluation of the quality and efficacy of generic drugs. Tamoxifen Citrate Tablets are listed in the National Medical Insurance Catalogue (2024 Edition) as a Class A Pharmaceutical and belong to the class of non-steroidal anti-estrogen drugs, used for the treatment of recurrent or metastatic breast cancer and as adjuvant therapy after surgery for early breast cancer.
Fudan Fuhua: Shanghai Fudan Fuhua Technology Co., Ltd. 2024 Annual Results Forecast
Shanghai Fudan Fuhua Technology Co., Ltd. 2024 Annual Results Forecast
Shanghai Fudan Forward S&T (600624.SH): Expected net loss in 2024 is 80 million to -0.12 billion yuan.
On January 23, Gelonghui reported that Shanghai Fudan Forward S&T (600624.SH) announced that 1. According to preliminary estimates by the finance department, the expected net income attributable to shareholders of the listed company for the year 2024 is projected to be between -120 million yuan and -80 million yuan, indicating a loss compared to the same period last year. 2. The expected net income attributable to shareholders of the listed company for the year 2024, after excluding non-recurring gains and losses, is projected to be between -127 million yuan and -85 million yuan. 1. Affected by changes in policies within the pharmaceutical Industry, as well as the decline in procurement prices and bidding prices of certain key products, the company's controlling subsidiary, SHANGHAI FUDAN.
We Think Shanghai Fudan Forward S&T (SHSE:600624) Has A Fair Chunk Of Debt
Is Shanghai Fudan Forward S&T (SHSE:600624) Using Too Much Debt?